Infliximab in the treatment of Crohn's disease: A user's guide for clinicians

American Journal of Gastroenterology

Volumn 97, Issue 12, 2002, Pages 2962-2972

  Sandborn, William J ^a,b   Hanauer, Stephen B ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHIMERIC ANTIBODY; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; DIPHENHYDRAMINE; DNA ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PARACETAMOL; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTHRALGIA; CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FACE EDEMA; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INTESTINE FISTULA; LUPUS ERYTHEMATOSUS; MAINTENANCE THERAPY; MYALGIA; PRIORITY JOURNAL; PRURITUS; RASH; REMISSION; RESPIRATORY DISTRESS; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SIDE EFFECT; SORE THROAT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; URTICARIA;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HUMANS; PRACTICE GUIDELINES;

EID: 0036897225     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)05510-7     Document Type: Review

References (75)

1. Hanauer SB, Sandborn W, for The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96:635-43.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
5. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
6. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
7. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
8. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
9. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol 2001;96:722-9.
10. Ricart E, Panaccione R, Loftus EV, et al. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999;117:429-32.
11. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 2000;59:428-33.
12. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
13. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
14. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187-93.
15. Tan MH, Gordon M, Lebwohl O, et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001;137:930-3.
16. Hanauer S, Lichtenstein G, Mayer L, et al. Extraintestinal manifestations of Crohn's disease: Response to infliximab (Remicade) in the ACCENT I trial through 30 weeks. Am J Gastroenterol 2001;96:S296-S297.
17. Hong J, Merel N, Hanauer S. Treatment of pyoderma gangrenosum (PG) complicating Crohn's disease (CD) with infliximab. Gastroenterology 2001;120:A621 (abstract).
18. Miller AM, Elliott PR, Fink R, Connell W. Rapid response of severe refractory metastatic Crohn's disease to infliximab. J Gastroenterol Hepatol 2001;16:940-2.
19. van Dullemen HM, de Jong E, Slors F, et al. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: Report of two cases. Dis Colon Rectum 1998;41:98-102.
20. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001;7:38-42.
21. Fefferman DS, Shah SA, Alsahlil M, et al. Successful treatment of refractory esophageal Crohn's disease with infliximab. Dig Dis Sci 2001;46:1733-5.
22. Heller T, James SP, Drachenberg C, et al. Treatment of severe esophageal Crohn's disease with infliximab. Inflamm Bowel Dis 1999;5:279-82.
23. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
24. Su CG, Salzberg B, Lewis J, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2001;96:S310 (abstract).
25. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001;7:83-8.
26. Probert SJL, Hearing SD, Schreiber S, et al. Infliximab in steroid-resistant ulcerative colitis: A randomised controlled trial. Gastroenterology 2002;122:A99 (abstract).
27. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
28. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
29. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
30. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
31. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
32. Sands B, Van Deventer S, Bernstein C, et al. Long-term treament of fistulizing Crohn's disease: Response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002;122:A81 (abstract).
33. Remicade (infliximab) for IV injection. Package Insert 2002. Centocor, Inc., Melvern, PA.
34. McCabe R, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996;110:A962 (abstract).
35. Rutgeerts P, Mayer L, Schreiber S, et al. Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn's disease. Am J Gastroenterol 2001;96:S302-S303.
36. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
37. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
38. Mayer L, Han C, Bala M, et al. Three dose induction regimen of infliximab: Remicade is superior to a single dose in patients with Crohn's disease (CD). Am J Gastroenterol 2001;96:S303 (abstract).
39. Wagner C, Olson A, Ford J, et al. Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohn's disease. Gastroenterology 2002;122: A613-A614 (abstract).
40. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: Risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
41. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-602.
42. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5:119-33.
43. Hanauer S, Schreiber S, Bao W, et al. ACCENT I trial: Infliximab response rates over 30 weeks. Am J Gastroenterol 2001;96:S302 (abstract).
44. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001;121:1064-72.
45. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med 2001;135:906-18.
46. The diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998;101: S465-S528.
47. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97(suppl 1):79-83.
48. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-62.
49. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18:465-71.
50. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: Report of a case. Am J Gastroenterol 2000;95: 2395-6.
51. O'Connor M, Buchman A, Marshall G. Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease. Dig Dis Sci 2002;47:1323-5.
52. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001;7:34-7.
53. Stafford CT. Life-threatening allergic reactions. Anticipating and preparing are the best defenses. Postgrad Med 1989;86: 235-42, 245.
54. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997;278:1895-906.
55. Valdez R, Peltier M, McCabe R. Safe home-care administration of infliximab. Gastroenterology 201;120:A-620 (abstract).
56. Norman M, Baert F, Vermeire S, et al. Post infusion infliximab levels determine duration of response in Crohn's disease and are directly related to infusion reactions. Gastroenterology 2002;122:A-100 (abstract).
57. Hanauer S, Rutgeerts P, Targan S, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology 1999;116:A731 (abstract).
58. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000;14(suppl C):29C-32C.
59. Panaccione R. Overcoming "delayed-type hypersensitivity reactions" in patients receiving repeated doses of infliximab: A report of 5 cases. Gastroenterology 2002;122:A-613 (abstract).
60. Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002;8:186-91.
61. Remicade (Infliximab). Prescribing Information. Physicians Desk Reference Medical Economics, Inc., Montvale, NJ. 2001:1085-8.
62. Norman M, Baert F, D'Haens G, et al. HACA formation after infliximab (Remicade) treatment in Crohn's disease is clearly associated with infusion reactions. Gastroenterology 2001; 120:A261 (abstract).
63. Farrell R, Alsahli M, Falchuk K, et al. Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy. Gastroenterology 2001;120:A-69 (abstract).
64. Farrell R, Alsahli M, Falchuk K, et al. A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapy. Gastroenterology 2001;120:A618-A619 (abstract).
65. Alsahli M, Jeen YTJ, Peppercorn MA, et al. A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapy. Gastroenterology 2002;122:A-100 (abstract).
66. Vermeire S, Norman M, Van Assche G, et al. Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation. Gastroenterology 2001;120:A-69 (abstract).
67. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
68. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
69. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78.
70. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002;34:410-2.
71. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 2000; 95:841-2.
72. Targeted tuberculin testing and treatment of latent tuberculosis infection. Official Statement of the American Thoracic Society, adopted by the American Thoracic Society Board of Directors, July 1999. Joint Statement of the American Thoracic Society and the Centers for Disease Control and Prevention, endorsed by the Council of the Infectious Diseases Society of America, September 1999. Am J Respir Crit Care Med 2000;161:S221-S247.
73. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149: 1359-74.
74. Mow WS, Abreu MT, Papadakis KA, et al. High incidence of anergy limits the usefullness of PPD screening for tuberculosis (TB) prior to Remicade in inflammatory bowel disease (IBD). Gastroenterology 2002;122:A-100 (abstract).
75. Diagnostic standards and classification of tuberculosis in adults and children. Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention, adopted by the American Thoracic Society Board of Directors, July 1999. Endorsed by the Council of the Infectious Diseases Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95.